TruSight Oncology 500 Portofolio

The AmpliSeq module within the TruSight Oncology 500 Portfolio is more than a test; it’s a transformative tool that tailors oncological treatments and assesses hereditary mutation risks within families. By offering unparalleled insights, it empowers healthcare providers and individuals to make informed decisions, ushering in a new era of personalized healthcare.

Whether you seek diagnostic support for precise treatment or predictive analysis for family-wide risk assessments, AmpliSeq is your ally in the journey towards more informed and personalized healthcare decisions. Illuminate the path to a healthier future with TruSight Oncology 500 Portfolio by Illumina.

Comprehensive BRCA1/2 Analysis:

AmpliSeq goes beyond conventional testing, employing Next-Generation Sequencing (NGS) to provide in-depth analysis of BRCA1/2 germline mutations. This information is pivotal in guiding targeted therapies and informing decisions on surgical interventions for optimal cancer management.

Diagnostic Support:

Conducted directly on patients, AmpliSeq serves as a powerful tool for determining the most effective precision oncology treatment. It unravels the genetic intricacies of individual cases, contributing to tailored and effective therapeutic approaches.

Predictive Analysis for Families:

AmpliSeq extends its impact to family members, conducting predictive analysis to assess the likelihood of inherited mutation risks. This not only aids in proactive healthcare planning but also plays a crucial role in identifying potential risks within family networks.

• Tissue Samples for Patients
• Blood Samples for Family Members

These varied examination types, coupled with a versatile range of sample sources, underscore the adaptability and inclusivity of AmpliSeq within the TruSight Oncology 500 Portfolio.